Further Advances in the Management of Anaplastic Lymphoma Kinase–Mutated Non–Small-Cell Lung Cancer
Author:
Affiliation:
1. Sai-Hong Ignatius Ou, University of California Irvine School of Medicine, Orange, CA
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2017.73.1323
Reference36 articles.
1. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2. Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
3. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
4. Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung Cancer
5. First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC;Journal of Translational Medicine;2022-05-31
2. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer;Clinical Lung Cancer;2020-05
3. CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome;Lung Cancer;2019-04
4. Pacific Rim redux: lorlatinib, the ultimate Jaeger?;Annals of Translational Medicine;2018-11
5. The allure of ‘ALUR’;Annals of Oncology;2018-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3